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Summary
Using domain switch chimeric antibodies, we confirm the important role of CH2 in comple-
ment activation. In addition, we demonstrate that the structures responsible for the differential
ability of human IgG1 and IgG4 to activate complement are located at the COOH-terminal
part (from residue 292 to 340) of the CH2 domain. The amino acids in CH2 that might be
involved in complement interaction are discussed. While CH3 contributes to efficient complement
activation, CH3 from IgG2 and CO IgG3 are equally effective.
T
he ability to activate the complement cascade and thereby
remove pathogenic agents is one of the most important
effector functions of the antibody molecule. IgM and IgG
are the only isotypes that activate the classical complement
pathway. The four humanIgG isotypes have very similar amino
acid sequences, but differ markedly in their ability to activate
complement. IgG3 and IgG1 are effective in activating com-
plement, IgG2 fixes complement poorly, and IgG4 appears
completely deficient in the ability to activate complement (1,
2). An unresolved question is what amino acid differences
determine this isotype-specific complement activation.
The hinge region shows the most sequence variation among
the IgG isotypes (2, 3). The hinge serves to both covalently
link the two heavy chains and to endow the antibody mole-
cule with segmental flexibility. We and others have shown
that a hinge region is essential for Clq binding and comple-
ment activation (3, 4) . However, the flexibility of the hinge
does not directly correlate with proficiency in complement
activation, and replacing the rigid hinge of IgG4 with the
flexible hinge of IgG3 did not result in an IgG4 molecule
that can activate complement (3). Therefore, while the hinge
region may modulate the ability of the IgG molecule to acti-
vate complement, it does not appear to determine the isotype-
specific differences.
Studies using antibody fragments suggested that the CH2
domain plays an important role in complement activation.
Facb (IgG depleted of CH3) and CH2 fragments bind C1 and
activate complement, while Fab and CH3 fragments did not
show any activity (5-7). Moreover, aglycosylated IgG lacking
carbohydrate in CH2 is unable to activate complement (8, 9).
While these experiments indicate that CH2 is primarily
responsible for C1 binding and complement activation, CH2
is not the only structure required. IgG that lacks CH3 is only
50% as efficient in its ability to activate complement as in-
tact IgG (5, 7). Moreover, while Glu 318, Lys 320, and Lys
322 in CH2 have been shown by in vitro mutagenesis to be
important for complement activation (10), these residues are
conserved among isotypes that do and do not activate com-
plement, and thus could not determine the isotype-specific
differences.
In this study, we have used domain exchange molecules
to further investigate the residues responsible for the isotype-
specific variation in complementactivation. We confirm that
CH2 appears to be the domain important for complement ac-
tivation. Furthermore, we provide evidence that the 000H-
terminal part (residues 292-340) of the CH2 domain contains
the residues responsible for the isotype-specific differences in
complement activation.
Materials and Methods
Construction ofChimeric IgG Molecules.
￿
The expressed VK and
V genes from the mouse antidansyl (DNS) hybridoma 27-44
were joined to human C, in the pSV2AHneo expressionvector and
to human IgG C in the pSV2AHgpt vector, respectively (11). As
shown in Fig. 1, a novel Pvul site was generated between exons
in the IgG2 and IgG3 constant region genes such that each gene
contains one Pvul site. The C1 and CH3 domain switch constant
region genes were produced using clones with the appropriate Pvul
sites. A Pvul site located between the hinge and C,,2 exons and
a SacII site between the C2 and CH3 exons were used to generate
the CH2 domain switch genes. IgG1 and IgG4 domain switch
genes were generated using a SaclI site located within the CH2
exon. The domain switch heavy chain genes were cloned into the
pSV20Hgpt expression vector and transfected with their specific
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Schematic diagram ofthe domain switch chimeric antibodies,
Up arrows (t) represent SaclI sites and down arrows (1) represent Pvul
sites, which were introduced by using oligonucleotide linkers . All heavy
chain constant regions were joined to the murine antidansyl variable re-
gion . Mutants with exon exchanges are given a four-digit name : the first
digit refers to the subclass of the C1 domains, and the second, third,
and fourth digits indicate the subclasses of the hinge, C.2, and C3 do-
mains, respectively. WT indicates the wild-type gene.
light chain gene into the Ig nonproducing cell line, P3X63Ag8.653,
by either protoplast fusion or electroporation (12) . The clones were
selected in medium containing the antibiotic G418 and screened
for antibody production by ELISA. Chimeric antidansyl antibodies
were purified by affinity chromatography.
Complement-mediated Hemolysis . SRBC were coated with
DNS/BSA and incubated with "Cr-sodium chromate (Amersham
Corp ., Arlington Heights, IL) . The free "Cr-sodium chromate
was removed by washing the cells three times in 10 ml of fresh
Gel-HBS buffer (0.01M Hepes, 0.15 M NaCl, 0.15 mM CaCl 2 ,
0.5 MM MgCl2, 0.1% gelatin, pH 7.4). Twofold serial dilutions
ofchimeric antibodies in Gel-HBS buffer were added to the round-
bottomed, 96-well plate (Corning Glass Works, Corning, NY) in
a volume of 50 P .1. 50 Al of2% "Cr-loaded SRBC and 25 Al of
2 U CHso of guinea pig complement (Colorado Serum Co.,
Denver, CO)were added to each well sequentially. The plates were
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￿
Complement consumption by IgGlAgG4 domain switch an-
tibodies . 8 ttg of antibodies was incubated with the indicated amount of
DNA/BSA in the presence ofguinea pig complement at 37°C for 45 min .
51Cr-loaded, hemolyysn-sensitized SRBC were added, incubated for 45
min, and the 51Cr released was used to determine the percentage of com-
plement consumption .
incubated at 37°C for 45 min, unlysed SRBC were pelleted by cen-
trifugation of the plate, and 50 pl supernatant was counted in a
gamma counter. The percentage of cell lysis was determined .
Complement Consumption Assay .
￿
To assaycomplement consump-
tion, 8 Ag of chimeric antibody was incubated with increasing
amounts ofDNS/BSA and 2U CHso of complement at 37°C for
45 min . "Cr-loaded hemolyin-sensitized SRBC were then added
and incubated for another 45 min . After centrifugation, theamount
of released "Cr was determined . Antibody only, antigen only,
buffer, and water controls were included in the experiments. The
percentage of complement consumption was calculated as : 100x
[(1 - cpmofAg + Ab complement)/(cpm ofAb + complement)] .
Results
A set of mouse-human chimeric antibodies having iden-
tical antigen-combining sites and light chain but with con-
stant region domains switched between IgG2 and IgG3 or
IgG1 and IgG4 were generated as described above. Fig . 1 is
a schematic diagram of the genetic structures of the anti-
body constant regions .
To locate the domain responsible for complement activa-
tion, domains were changed between IgG2 and IgG3, and
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￿
Complement-mediated hemolysis of
IgG2 and IgG3 domain switch antibodies . For
clarity of presentation, the data areshown in two
panels . 51Cr-loaded, DNS/BSA-coated SRBC
were lysed by various concentrations of antibody
in the presence ofguinea pig complement, and the
percentages of cell lysis was calculated . The struc-
ture of the chimeric antibodies is shown in Fig. 1 .
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Three-dimensional structure of human IgG1 Fc. Aminoacids
that are discussed in the text are indicated as solid balls. Ala 327 is buried
in the molecule . This graphic is made using the MacImdad program and
is based on the coordinates from Deisenhofer (14). The twoC2domains
face in opposite directions . Therefore, Glu 318, Lys 320, Lys 322, Ala 330,
and Pro 331 are invisible on the other side of the left domain, and Tyr
296 is similarly hidden on the other side ofthe C.2 domain on the right.
the ability of the resulting antibodies to mediate complement-
dependent cell lysis ofSRBC coated with the hapten dansyl
was measured . As shown in Fig . 2 A, replacement of the
C1 and C3 domains ofIgG2 with the corresponding do-
mains from IgG3, IgG(3-2-2-2), and IgG(2-2-2-3), did not
increase the complement binding activity. However, IgG(2-
2-3-2) containing the C.2 domain from IgG3 performs
complement-mediated cell lysis almost as well as wild-type
IgG3 . Likewise, the replacement of the C2 domain of IgG3
with the corresponding domain from IgG2, IgG(3-3-2-3),
completely abolished the capacity to fix complement (Fig.
2 B) . These results clearly demonstrate that the structures
that determine the differing ability of IgG2 and IgG3 to ac-
tivate complement are largely located in the C2 domain .
To further localize the region of the C2 domain that de-
termines its ability to activate complement, a SacII site in
the C2 exon of the heavy chain genes of IgG1 and IgG4
was used to generate intra-domain switch antibodies between
IgG1 and IgG4 (Fig . 1) . The SacII site is located at residue
292 in C.2 ; thus, IgG(1-1-1/4-4) has the COOH-terminal
part (from residue 292-340) of the C2 domain and the C.3
domains from IgG4 . The same region in IgG(4-4-4/1-1) is
from IgG1 . The more sensitive complement consumption
assay was used to measure the effect of domain switch be-
tween IgG1 and IgG4 in order to detect small amounts of
residual activity. It was found that IgG(1-1-1/4-4) completely
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lost its ability to activate complement ; in contrast, IgG(4-4-
4/1-1) showed significant activity compared with wild-type
IgG4 (Fig . 3) . These results indicate that residues 292-340
in C.2 contain amino acids determining the isotype-specific
differences in complement activation .
Discussion
ThehumanIgG molecules differ markedly in their ability
to activate complement in spite of having very similar amino
acid sequences . The important role of the C2 domain of
IgG in complement activationwas supported by earlier anti-
body fragmentation studies (5-7) . The contribution by C.3
was also indicated with the finding that C.3 could stabilize
the conformation of Cl and protect it from attack by the
C1 inhibitor (13) . The studies reported here show that it is
the C,2 but not CF,3 that determines the human IgG iso-
type-specific differences in complement activation. Moreover,
our studiesnow locate the important residues to theCOOH
terminus of the C2 domain between residues 292 and 340 .
Within that region, IgG1 differs from IgG4 at only four
residues : 296 (Tyr vs. Phe), 327 (Ala vs. Gly), 330 (Ala vs .
Ser), and 331 (Pro vs. Ser) . The locations ofthese amino acids
in the three-dimensional structure of IgG1 Fc are shown in
Fig . 4 . Using the nomenclature of Beale and Feinstein (15),
residues 330 and 331 are located on the Fy3 ß strand and
fold into proximity with the previously identified 318-320-
322 residues (10) . Therefore, these residues together may pro-
vide the binding site for C1q. The side chain of residue 327
is mostly buried inside the molecule and is probably not
directly involved in Clq binding. However, the greater flexi-
bility afforded by the Gly residue in IgG4 may change the
conformation ofthe nearby Clq binding site and thus affect
complement activation . Residue 296 is located on the sur-
face of X face. It seems unlikely that a Clq molecule can
bind the proposed binding site on Y face and residue 296
simultaneously. However, residue 296 in the other C2 is
quite accessible, as shown in Fig. 4, and might contribute
to the Clq binding site . The fact that both C.2 domains are
required forC1 activation give indirect support for this pos-
sibility (5) .
Noteworthy is the fact that the IgG(4-4-4/1-1) molecule
is slightly deficient in its ability to activate complement rela-
tive to wild-type IgG1 . A significant difference between the
two molecules is in the hinge region . It is quite possible that
the rigid hinge of IgG4 impairs access to the Clq binding
site thus decreasing the effectiveness ofthe molecule. We have
observed a similar modulating effect of the hinge region on
FcyRI binding (Canfield, S . M ., and S. L. Morrison, manu-
script submitted for publication) . Alternatively, additional
amino acid variation between the two isotypes within the
C.2 NH2 terminal to the exchange point may further
influence complement activation .
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